IceCure Medical (ICCM) to Release Quarterly Earnings on Tuesday

IceCure Medical (NASDAQ:ICCM) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect IceCure Medical to post earnings of ($0.04) per share and revenue of $1.30 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 11:00 AM ET.

IceCure Medical Trading Up 8.9%

NASDAQ:ICCM opened at $0.67 on Thursday. The company has a market cap of $45.96 million, a P/E ratio of -2.57 and a beta of 0.29. IceCure Medical has a twelve month low of $0.54 and a twelve month high of $1.53. The company’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.76.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $2.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Virtu Financial LLC acquired a new position in IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned 0.09% of IceCure Medical as of its most recent filing with the Securities & Exchange Commission. 0.62% of the stock is owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.